0.83
-0.1277(-13.39%)
Currency In USD
| Previous Close | 0.95 |
| Open | 0.94 |
| Day High | 0.95 |
| Day Low | 0.76 |
| 52-Week High | 4.28 |
| 52-Week Low | 0.6 |
| Volume | 547,546 |
| Average Volume | 1.47M |
| Market Cap | 38.48M |
| PE | -0.76 |
| EPS | -1.08 |
| Moving Average 50 Days | 1.51 |
| Moving Average 200 Days | 1.35 |
| Change | -0.13 |
If you invested $1000 in Reviva Pharmaceuticals Holdings, Inc. (RVPH) since IPO date, it would be worth $85.08 as of April 01, 2025 at a share price of $0.826. Whereas If you bought $1000 worth of Reviva Pharmaceuticals Holdings, Inc. (RVPH) shares 5 years ago, it would be worth $78.23 as of April 01, 2025 at a share price of $0.826.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
GlobeNewswire Inc.
Mar 30, 2025 3:30 PM GMT
CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CN
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 04, 2025 1:00 PM GMT
CUPERTINO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of
Reviva to Participate in the 2025 BIO CEO & Investor Conference
GlobeNewswire Inc.
Jan 30, 2025 1:00 PM GMT
CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of